Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

By S. Paik, G. Tang, S. Shak, Chungyeul Kim, J. Baker, W. Kim, M. Cronin, Frederick L. Baehner, D. Watson, J. Bryant and 4 more. Journal of Clinical Oncology, 2006

2,514 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/0bd8c814c31d8fc824da0974fbce3f769e3a8042

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Balázs Győrffy
2. A. Lánczky
3. J. Reis-Filho
4. Aleix Prat
5. Howard Y. Chang
6. Ian O. Ellis
7. A. Lluch
8. Eran Segal

In Genetics

1. J. Reis-Filho
2. Eran Segal
3. S. Taube
4. Howard Y. Chang
5. Gary A. Churchill
6. Balázs Győrffy
7. Xiaofeng Dai
8. N. Rosenfeld

In Pathology and Forensic Medicine

1. Balázs Győrffy
2. A. Lánczky
3. Aleix Prat
4. J. Reis-Filho
5. Frederick L. Baehner
6. Ian O. Ellis

Citations in the corpus

• Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients (2007, methodology): “…tamoxifentreated BC population enrolled in the National Surgical Adjuvant Breast and Bowel Project B-14 (NSABP B-14), as well to predict the magnitude of chemotherapy benefit in women with node-negative, estrogen receptor (ER)-positive BC enrolled in the NSABP B20 trial (Paik et al, 2004, 2006).”
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013, methodology): “benefit from the addition of chemotherapy in node-negative [75] or node-positive [76] disease.”
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, methodology): “Gene expression profiles such as Mammaprint or Oncotype Dx Recurrence Score may be used to gain additional prognostic and/or predictive information to complement pathology assessment and to predict response to adjuvant chemotherapy, in particular in patients with ER-positive early breast cancer [II,”
• Breast cancer intrinsic subtype classification, clinical use and future trends. (2015, methodology): “Oncotype DX measures the expression of 21 genes, including 16 cancer-related and 5 reference genes [30, 47].”
• Breast cancer prognostic classification in the molecular era: the role of histological grade (2010, background): “Recent studies leading to the development of the 21-gene recurrence score (trade name Oncotype DX; Genomic Health, Inc., Redwood City, CA, USA [22, 23 ]) have highlighted the issue of subjec tivity associated with histological grading and called into question the utility of histological grade as a p”
• Decoding global gene expression programs in liver cancer by noninvasive imaging (2007, methodology): “For instance, in breast cancer, a 21-gene assay, termed Oncotype Dx, is commercially available to determine prognosis and predict response of primary breast tumors to chemotherap”
• MicroRNAs accurately identify cancer tissue origin (2008, background): “Discussion Gene expression profiles have recently become a basis for diagnostic, prognostic and predictive informatio”